vs
Side-by-side financial comparison of CytomX Therapeutics, Inc. (CTMX) and R F INDUSTRIES LTD (RFIL). Click either name above to swap in a different company.
R F INDUSTRIES LTD is the larger business by last-quarter revenue ($22.7M vs $18.7M, roughly 1.2× CytomX Therapeutics, Inc.). R F INDUSTRIES LTD runs the higher net margin — 0.8% vs -0.8%, a 1.6% gap on every dollar of revenue. On growth, R F INDUSTRIES LTD posted the faster year-over-year revenue change (22.9% vs -25.7%). R F INDUSTRIES LTD produced more free cash flow last quarter ($2.0M vs $-15.8M). Over the past eight quarters, R F INDUSTRIES LTD's revenue compounded faster (29.8% CAGR vs -15.9%).
CytomX Therapeutics is a clinical-stage biotechnology company specializing in innovative cancer immunotherapies. It leverages its proprietary Probody technology platform to develop targeted therapies that activate exclusively in tumor microenvironments, minimizing off-target toxicities, with a pipeline covering multiple solid tumor indications and partnerships with leading global pharmaceutical firms.
Tootsie Roll Industries is an American manufacturer of confectionery based in Chicago, Illinois. Its best-known products include the namesake Tootsie Rolls and Tootsie Pops. Tootsie Roll Industries currently markets its brands internationally in Canada, Mexico, and over 75 other countries.
CTMX vs RFIL — Head-to-Head
Income Statement — Q2 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $18.7M | $22.7M |
| Net Profit | $-154.0K | $173.0K |
| Gross Margin | — | 36.8% |
| Operating Margin | -6.9% | 4.0% |
| Net Margin | -0.8% | 0.8% |
| Revenue YoY | -25.7% | 22.9% |
| Net Profit YoY | 97.6% | 172.7% |
| EPS (diluted) | — | $0.01 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $22.7M | ||
| Q3 25 | — | $19.8M | ||
| Q2 25 | $18.7M | $18.9M | ||
| Q1 25 | $50.9M | $19.2M | ||
| Q4 24 | $38.1M | $18.5M | ||
| Q3 24 | $33.4M | $16.8M | ||
| Q2 24 | $25.1M | $16.1M | ||
| Q1 24 | $41.5M | $13.5M |
| Q4 25 | — | $173.0K | ||
| Q3 25 | — | $392.0K | ||
| Q2 25 | $-154.0K | $-245.0K | ||
| Q1 25 | $23.5M | $-245.0K | ||
| Q4 24 | $18.9M | $-238.0K | ||
| Q3 24 | $5.7M | $-705.0K | ||
| Q2 24 | $-6.5M | $-4.3M | ||
| Q1 24 | $13.8M | $-1.4M |
| Q4 25 | — | 36.8% | ||
| Q3 25 | — | 34.0% | ||
| Q2 25 | — | 31.5% | ||
| Q1 25 | — | 29.8% | ||
| Q4 24 | — | 31.3% | ||
| Q3 24 | — | 29.5% | ||
| Q2 24 | — | 29.9% | ||
| Q1 24 | — | 24.5% |
| Q4 25 | — | 4.0% | ||
| Q3 25 | — | 3.6% | ||
| Q2 25 | -6.9% | 0.6% | ||
| Q1 25 | 44.4% | 0.3% | ||
| Q4 24 | 46.4% | 0.5% | ||
| Q3 24 | 12.3% | -2.5% | ||
| Q2 24 | -33.7% | -2.6% | ||
| Q1 24 | 28.1% | -15.5% |
| Q4 25 | — | 0.8% | ||
| Q3 25 | — | 2.0% | ||
| Q2 25 | -0.8% | -1.3% | ||
| Q1 25 | 46.2% | -1.3% | ||
| Q4 24 | 49.6% | -1.3% | ||
| Q3 24 | 17.2% | -4.2% | ||
| Q2 24 | -26.0% | -26.7% | ||
| Q1 24 | 33.3% | -10.1% |
| Q4 25 | — | $0.01 | ||
| Q3 25 | — | $0.04 | ||
| Q2 25 | — | $-0.02 | ||
| Q1 25 | — | $-0.02 | ||
| Q4 24 | — | $-0.02 | ||
| Q3 24 | — | $-0.07 | ||
| Q2 24 | — | $-0.41 | ||
| Q1 24 | — | $-0.13 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $49.0M | $5.1M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $119.9M | $35.2M |
| Total Assets | $175.1M | $73.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $5.1M | ||
| Q3 25 | — | $3.0M | ||
| Q2 25 | $49.0M | $3.6M | ||
| Q1 25 | $47.6M | $1.3M | ||
| Q4 24 | $38.1M | $839.0K | ||
| Q3 24 | $40.6M | $1.8M | ||
| Q2 24 | $43.2M | $1.4M | ||
| Q1 24 | $36.2M | $4.5M |
| Q4 25 | — | $35.2M | ||
| Q3 25 | — | $34.8M | ||
| Q2 25 | $119.9M | $34.2M | ||
| Q1 25 | $25.0M | $34.2M | ||
| Q4 24 | $-456.0K | $34.1M | ||
| Q3 24 | $-23.5M | $34.1M | ||
| Q2 24 | $-31.2M | $34.6M | ||
| Q1 24 | $-31.7M | $38.7M |
| Q4 25 | — | $73.0M | ||
| Q3 25 | — | $73.2M | ||
| Q2 25 | $175.1M | $72.7M | ||
| Q1 25 | $98.5M | $70.4M | ||
| Q4 24 | $120.5M | $71.0M | ||
| Q3 24 | $139.0M | $71.9M | ||
| Q2 24 | $159.2M | $72.8M | ||
| Q1 24 | $184.7M | $79.1M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-15.8M | $2.1M |
| Free Cash FlowOCF − Capex | $-15.8M | $2.0M |
| FCF MarginFCF / Revenue | -84.6% | 9.0% |
| Capex IntensityCapex / Revenue | 0.1% | 0.3% |
| Cash ConversionOCF / Net Profit | — | 12.13× |
| TTM Free Cash FlowTrailing 4 quarters | $-77.7M | $4.3M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $2.1M | ||
| Q3 25 | — | $-311.0K | ||
| Q2 25 | $-15.8M | $2.2M | ||
| Q1 25 | $-21.0M | $601.0K | ||
| Q4 24 | $-19.9M | $-244.0K | ||
| Q3 24 | $-20.7M | $2.4M | ||
| Q2 24 | $-19.5M | $197.0K | ||
| Q1 24 | $-26.0M | $840.0K |
| Q4 25 | — | $2.0M | ||
| Q3 25 | — | $-419.0K | ||
| Q2 25 | $-15.8M | $2.2M | ||
| Q1 25 | $-21.2M | $574.0K | ||
| Q4 24 | $-20.0M | $-418.0K | ||
| Q3 24 | $-20.7M | $2.1M | ||
| Q2 24 | $-19.6M | $28.0K | ||
| Q1 24 | $-26.2M | $697.0K |
| Q4 25 | — | 9.0% | ||
| Q3 25 | — | -2.1% | ||
| Q2 25 | -84.6% | 11.4% | ||
| Q1 25 | -41.6% | 3.0% | ||
| Q4 24 | -52.5% | -2.3% | ||
| Q3 24 | -62.1% | 12.6% | ||
| Q2 24 | -78.2% | 0.2% | ||
| Q1 24 | -63.1% | 5.2% |
| Q4 25 | — | 0.3% | ||
| Q3 25 | — | 0.5% | ||
| Q2 25 | 0.1% | 0.2% | ||
| Q1 25 | 0.2% | 0.1% | ||
| Q4 24 | 0.2% | 0.9% | ||
| Q3 24 | 0.1% | 1.5% | ||
| Q2 24 | 0.4% | 1.0% | ||
| Q1 24 | 0.3% | 1.1% |
| Q4 25 | — | 12.13× | ||
| Q3 25 | — | -0.79× | ||
| Q2 25 | — | — | ||
| Q1 25 | -0.89× | — | ||
| Q4 24 | -1.05× | — | ||
| Q3 24 | -3.61× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -1.89× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CTMX
| Bristol Myers Squibb Company | $11.6M | 62% |
| Astellas Pharma Inc | $4.6M | 25% |
| Regeneron Pharmaceuticals Inc | $2.1M | 11% |
RFIL
| US | $20.9M | 92% |
| Non Us | $1.8M | 8% |
